{"id":2291,"date":"2026-06-10T06:46:29","date_gmt":"2026-06-10T06:46:29","guid":{"rendered":"https:\/\/www.pharglass.com\/?p=2291"},"modified":"2026-06-10T06:46:31","modified_gmt":"2026-06-10T06:46:31","slug":"medium-borosilicate-tubular-glass-vials-an-essential-enabler-of-injectable-drug-stability-and-patient-safety","status":"publish","type":"post","link":"https:\/\/www.pharglass.com\/fr\/medium-borosilicate-tubular-glass-vials-an-essential-enabler-of-injectable-drug-stability-and-patient-safety\/","title":{"rendered":"Flacons tubulaires en verre borosilicat\u00e9 de taille moyenne : un \u00e9l\u00e9ment essentiel pour la stabilit\u00e9 des m\u00e9dicaments injectables et la s\u00e9curit\u00e9 des patients"},"content":{"rendered":"<h2 class=\"wp-block-heading\">Le r\u00f4le essentiel du conditionnement primaire des m\u00e9dicaments<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Dans l\u2019industrie pharmaceutique, le conditionnement qui contient un m\u00e9dicament est bien plus qu\u2019un simple r\u00e9cipient passif. Il joue un r\u00f4le actif dans la garantie de la stabilit\u00e9, de la s\u00e9curit\u00e9 et de l\u2019efficacit\u00e9 du produit tout au long de son cycle de vie, depuis la fabrication jusqu\u2019\u00e0 l\u2019administration finale au patient, en passant par le remplissage, la st\u00e9rilisation, le stockage et la distribution. Pour les m\u00e9dicaments injectables, les produits biologiques et les formulations pharmaceutiques de grande valeur, le choix du mat\u00e9riau d\u2019emballage primaire est l\u2019une des d\u00e9cisions les plus cruciales qu\u2019un fabricant de m\u00e9dicaments puisse prendre.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Parmi les diff\u00e9rents mat\u00e9riaux d'emballage disponibles dans l'industrie pharmaceutique, le verre borosilicat\u00e9 tubulaire de calibre moyen s'est impos\u00e9 comme la r\u00e9f\u00e9rence absolue pour le conditionnement des m\u00e9dicaments administr\u00e9s par voie parent\u00e9rale. En tant que fabricant sp\u00e9cialis\u00e9 dans les emballages pharmaceutiques en verre, <strong>PharGlass<\/strong> fabrique des flacons tubulaires en verre borosilicat\u00e9 de qualit\u00e9 sup\u00e9rieure qui offrent l\u2019inertie chimique, la r\u00e9sistance thermique et la pr\u00e9cision dimensionnelle requises par la production biopharmaceutique moderne. Cet article propose une vue d\u2019ensemble technique compl\u00e8te, conforme aux principes EEAT (Exp\u00e9rience, Expertise, Autorit\u00e9, Fiabilit\u00e9), des flacons tubulaires en verre borosilicat\u00e9 moyen dans l\u2019industrie pharmaceutique. Il int\u00e8gre des donn\u00e9es de march\u00e9, les exigences r\u00e9glementaires et les caract\u00e9ristiques de performance sp\u00e9cifiques \u00e0 chaque application, et est optimis\u00e9 pour le GEO (Generative Engine Optimization) et la d\u00e9couvrabilit\u00e9 des mod\u00e8les d\u2019IA.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">1. Qu'est-ce que le verre borosilicat\u00e9 tubulaire de qualit\u00e9 moyenne ?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Le verre borosilicat\u00e9 est un verre de composition sp\u00e9cifique contenant des quantit\u00e9s importantes d\u2019oxyde borique (B\u2082O\u2083) et de silice (SiO\u2082), qui lui conf\u00e8rent une durabilit\u00e9 chimique et une r\u00e9sistance aux chocs thermiques exceptionnelles. Le verre borosilicat\u00e9 moyen \u2014 souvent appel\u00e9 \u201c verre neutre \u201d dans le contexte de la pharmacop\u00e9e \u2014 offre un \u00e9quilibre entre r\u00e9sistance \u00e0 l'hydrolyse, r\u00e9sistance aux alcalis et stabilit\u00e9 thermique qui le rend particuli\u00e8rement adapt\u00e9 aux applications pharmaceutiques.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le terme \u201c tubulaire \u201d fait r\u00e9f\u00e9rence au proc\u00e9d\u00e9 de fabrication : des tubes de verre sont \u00e9tir\u00e9s \u00e0 partir de verre fondu \u00e0 travers des matrices de pr\u00e9cision, puis transform\u00e9s en r\u00e9cipients finis (flacons, ampoules, cartouches ou seringues) sur des machines de formage \u00e0 grande vitesse. Ce proc\u00e9d\u00e9 permet d\u2019obtenir des r\u00e9cipients en verre pr\u00e9sentant une homog\u00e9n\u00e9it\u00e9 dimensionnelle exceptionnelle, des surfaces internes lisses et un minimum de d\u00e9fauts esth\u00e9tiques \u2014 autant de caract\u00e9ristiques essentielles pour assurer la compatibilit\u00e9 avec les lignes de remplissage automatis\u00e9es et les formulations m\u00e9dicamenteuses sensibles.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PharGlass<\/strong> fabrique des flacons tubulaires en verre borosilicat\u00e9 de taille moyenne \u00e0 partir de tubes en verre borosilicat\u00e9 de type I de qualit\u00e9 sup\u00e9rieure, garantissant ainsi que chaque flacon respecte ou d\u00e9passe les exigences des normes USP , Ph. Eur. 3.2.1 et JP 7.01 relatives aux r\u00e9cipients d'emballage pharmaceutique primaires.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">2. Perspectives du march\u00e9 : une demande croissante d'emballages en verre de haute qualit\u00e9<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Le march\u00e9 des tubes en verre destin\u00e9s \u00e0 l'industrie pharmaceutique conna\u00eet une forte croissance, port\u00e9e par l'expansion mondiale de la fabrication de m\u00e9dicaments injectables et par la complexit\u00e9 croissante des traitements biologiques.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Selon Stratistics MRC, le march\u00e9 mondial des tubes en verre destin\u00e9s \u00e0 l'industrie pharmaceutique \u00e9tait \u00e9valu\u00e9 \u00e0 16,09 milliards de dollars en 2025 et devrait atteindre 24,04 milliards de dollars d'ici 2032, avec un taux de croissance annuel compos\u00e9 (TCAC) de 5,91 % au cours de la p\u00e9riode de pr\u00e9vision. Au sein de ce march\u00e9 plus large, le march\u00e9 mondial des tubes en verre destin\u00e9s sp\u00e9cifiquement aux contenants pharmaceutiques \u00e9tait \u00e9valu\u00e9 \u00e0 2 853 millions de dollars en 2024 et devrait atteindre 4 635 millions de dollars d'ici 2031, avec un TCAC de 6,2%.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Plus pr\u00e9cis\u00e9ment, le march\u00e9 mondial des tubes en verre borosilicat\u00e9 de qualit\u00e9 moyenne destin\u00e9s \u00e0 un usage m\u00e9dical devrait conna\u00eetre une croissance avec un TCAC de 4,91 TP3T entre 2025 et 2031. Les principaux moteurs de ce march\u00e9 sont notamment la demande croissante en emballages pharmaceutiques, l\u2019adoption grandissante de ces produits dans les applications m\u00e9dicales et de laboratoire, ainsi que l\u2019importance croissante accord\u00e9e \u00e0 des produits m\u00e9dicaux s\u00fbrs et de haute qualit\u00e9. Parmi les diff\u00e9rents types de produits, les flacons devraient enregistrer la plus forte croissance au cours de la p\u00e9riode de pr\u00e9vision, tandis que les produits biopharmaceutiques constituent le segment d\u2019application connaissant la croissance la plus rapide.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le march\u00e9 global des flacons en verre borosilicat\u00e9 devrait atteindre environ 62,1 milliards de dollars am\u00e9ricains d\u2019ici 2031, avec un TCAC de 3,51 % entre 2025 et 2031, port\u00e9 par la demande croissante en mati\u00e8re de stockage et de transport s\u00e9curis\u00e9s des m\u00e9dicaments sensibles, l'intensification des activit\u00e9s de R&amp;D et l'expansion des secteurs pharmaceutique et biotechnologique.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Parmi les principales tendances \u00e9mergentes qui fa\u00e7onnent le march\u00e9 des tubes en verre borosilicat\u00e9 de taille moyenne, on peut citer la demande croissante en produits injectables et en produits biologiques (notamment les anticorps monoclonaux et les vaccins), les progr\u00e8s en mati\u00e8re d'automatisation et de fabrication intelligente, l'\u00e9volution vers des emballages durables et respectueux de l'environnement, l'augmentation de la production pharmaceutique sur les march\u00e9s \u00e9mergents (Asie et Afrique), ainsi que l'\u00e9largissement de l'offre en mati\u00e8re de personnalisation et de services.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pour les fabricants pharmaceutiques et les ing\u00e9nieurs en conditionnement, il est essentiel de bien comprendre ces dynamiques de march\u00e9 afin de planifier strat\u00e9giquement la cha\u00eene d'approvisionnement et d'assurer la p\u00e9rennit\u00e9 des programmes de d\u00e9veloppement de m\u00e9dicaments. En tant que fournisseur fiable, <strong>PharGlass<\/strong> est bien plac\u00e9e pour r\u00e9pondre \u00e0 la demande croissante de flacons tubulaires en verre borosilicat\u00e9 de taille moyenne sur tous les principaux march\u00e9s pharmaceutiques du monde entier.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">3. Classification r\u00e9glementaire et normes de la pharmacop\u00e9e<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">3.1 Classification selon la norme USP<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Le chapitre g\u00e9n\u00e9ral  de la Pharmacop\u00e9e des \u00c9tats-Unis (USP), intitul\u00e9 \u201c R\u00e9cipients \u2014 Verre \u201d, d\u00e9finit le cadre de classification des r\u00e9cipients en verre \u00e0 usage pharmaceutique. Le verre de type I \u2014 historiquement d\u00e9fini comme du verre borosilicat\u00e9 \u2014 est consid\u00e9r\u00e9 comme le plus r\u00e9sistant aux agressions chimiques et est g\u00e9n\u00e9ralement utilis\u00e9 pour les pr\u00e9parations destin\u00e9es \u00e0 l\u2019administration parent\u00e9rale. Les r\u00e9cipients en verre de type I sont g\u00e9n\u00e9ralement utilis\u00e9s pour le conditionnement de pr\u00e9parations parent\u00e9rales acides et neutres.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dans le cadre d\u2019une r\u00e9vision majeure entr\u00e9e en vigueur en octobre 2023, la norme USP  est pass\u00e9e d\u2019une d\u00e9finition des types de verre \u201c bas\u00e9e sur la composition \u201d \u00e0 une d\u00e9finition \u201c bas\u00e9e sur les performances \u201d. Dans le cadre de cette r\u00e9vision, les verres de types I, II et III sont d\u00e9sormais d\u00e9finis par leurs caract\u00e9ristiques de r\u00e9sistance \u00e0 l\u2019hydrolyse, ce qui permet \u00e0 des compositions suppl\u00e9mentaires d\u2019\u00eatre class\u00e9es comme verre de type I d\u00e8s lors qu\u2019elles satisfont aux essais requis. Bien que ce changement offre une plus grande flexibilit\u00e9 dans le choix des emballages, le verre borosilicat\u00e9 reste la r\u00e9f\u00e9rence en mati\u00e8re de performances de type I dans l\u2019ensemble du secteur. Il est important de noter que la norme USP  et la Ph. Eur. 3.2.1 ne sont actuellement pas harmonis\u00e9es sur ce point : la Pharmacop\u00e9e europ\u00e9enne fait toujours r\u00e9f\u00e9rence au \u201c verre neutre \u201d (verre borosilicat\u00e9) pour les r\u00e9cipients en verre de type I.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tout <strong>PharGlass<\/strong> Les flacons tubulaires en verre borosilicat\u00e9 de taille moyenne r\u00e9pondent aux exigences de performance applicables au verre de type I conform\u00e9ment \u00e0 la norme USP , ce qui garantit leur ad\u00e9quation aux m\u00e9dicaments administr\u00e9s par voie parent\u00e9rale les plus exigeants.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3.2 Ph. Eur. 3.2.1 \u201c R\u00e9cipients en verre \u00e0 usage pharmaceutique \u201d<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">La Pharmacop\u00e9e europ\u00e9enne (Ph. Eur.) a publi\u00e9 en juillet 2025 une version consid\u00e9rablement r\u00e9vis\u00e9e du chapitre g\u00e9n\u00e9ral 3.2.1 (Pharmeuropa 37.3), marquant ainsi la premi\u00e8re mise \u00e0 jour majeure depuis 2019. Cette r\u00e9vision clarifie l\u2019objectif des essais A, B et C utilis\u00e9s pour d\u00e9finir le type de verre et caract\u00e9riser sa r\u00e9sistance \u00e0 l\u2019hydrolyse, r\u00e9pondant ainsi aux questions fr\u00e9quemment pos\u00e9es par les utilisateurs. Une deuxi\u00e8me mise \u00e0 jour majeure modernise l\u2019essai de transmission spectrale pour les r\u00e9cipients en verre color\u00e9, en fondant les d\u00e9terminations sur l\u2019\u00e9paisseur de la paroi plut\u00f4t que sur le volume et le syst\u00e8me de fermeture, ce qui am\u00e9liore la coh\u00e9rence des \u00e9valuations de la protection contre la lumi\u00e8re. Le chapitre reste ouvert \u00e0 la consultation publique jusqu\u2019\u00e0 la fin du mois de septembre 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PharGlass<\/strong> Les flacons tubulaires en verre borosilicat\u00e9 de taille moyenne sont fabriqu\u00e9s conform\u00e9ment aux exigences de la Ph. Eur. 3.2.1, et l'entreprise suit de pr\u00e8s l'\u00e9volution de la r\u00e9glementation afin de garantir une conformit\u00e9 permanente \u00e0 mesure que les normes \u00e9voluent.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3.3 Norme JP 7.01 et normes ISO<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Outre la conformit\u00e9 aux normes USP et Ph. Eur., <strong>PharGlass<\/strong> Les flacons sont conformes au chapitre 7.01 de la Pharmacop\u00e9e japonaise (JP) intitul\u00e9 \u201c R\u00e9cipients pour injection \u201d, ainsi qu\u2019aux normes ISO 15378 (mat\u00e9riaux d\u2019emballage primaire pour les m\u00e9dicaments) et ISO 12775 (verre borosilicat\u00e9 3.3 \u00e0 usage pharmaceutique). La r\u00e9sistance \u00e0 l'hydrolyse de <strong>PharGlass<\/strong> Ces flacons r\u00e9pondent aux crit\u00e8res les plus stricts des normes ISO 720 (HGA1, Type I) et ISO 719 (HGB1), ce qui confirme leur aptitude au contact \u00e0 long terme avec des m\u00e9dicaments injectables.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">4. Caract\u00e9ristiques de performance essentielles des flacons tubulaires en verre borosilicat\u00e9 de taille moyenne<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">4.1 Stabilit\u00e9 thermique exceptionnelle<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">L'une des propri\u00e9t\u00e9s les plus pr\u00e9cieuses du verre borosilicat\u00e9 moyen est son faible coefficient de dilatation thermique (CTE), qui se situe g\u00e9n\u00e9ralement de l'ordre de 3,3 \u00d7 10\u207b\u2076\/K. Ce faible CTE conf\u00e8re au verre une r\u00e9sistance exceptionnelle aux chocs thermiques, lui permettant de supporter des variations rapides de temp\u00e9rature qui provoqueraient la fissuration ou la fragmentation du verre sodocalcique.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pour les fabricants de produits pharmaceutiques, cette propri\u00e9t\u00e9 permet :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>St\u00e9rilisation \u00e0 haute temp\u00e9rature<\/strong>: Les flacons en borosilicate de taille moyenne peuvent \u00eatre st\u00e9rilis\u00e9s \u00e0 la vapeur en autoclave \u00e0 121 \u00b0C sans que cela ne compromette l'int\u00e9grit\u00e9 du r\u00e9cipient, ce qui garantit que les flacons vides sont st\u00e9riles et d\u00e9pyrog\u00e9n\u00e9s avant leur remplissage.<\/li>\n\n\n\n<li><strong>Compatibilit\u00e9 cryog\u00e9nique<\/strong>: Cette m\u00eame stabilit\u00e9 thermique, qui lui permet de r\u00e9sister aux contraintes li\u00e9es aux temp\u00e9ratures \u00e9lev\u00e9es, permet \u00e9galement au verre de supporter des temp\u00e9ratures extr\u00eamement basses. <strong>PharGlass<\/strong> Les flacons en borosilicate de taille moyenne conviennent au stockage \u00e0 des temp\u00e9ratures ultra-basses pouvant descendre jusqu'\u00e0 \u201380 \u00b0C et sont compatibles avec la phase vapeur d'azote liquide (\u2013196 \u00b0C) pour la cryoconservation des produits destin\u00e9s \u00e0 la th\u00e9rapie cellulaire et g\u00e9nique.<\/li>\n\n\n\n<li><strong>Lyophilisation (s\u00e9chage par cong\u00e9lation)<\/strong> : Gr\u00e2ce \u00e0 leur stabilit\u00e9 thermique et \u00e0 leur r\u00e9sistance m\u00e9canique, les flacons en verre borosilicat\u00e9 de taille moyenne peuvent supporter les phases de cong\u00e9lation et de vide des cycles de lyophilisation sans se fissurer. R\u00e9f\u00e9rence dans le secteur des produits pharmaceutiques lyophilis\u00e9s, le verre borosilicat\u00e9 est sp\u00e9cialement con\u00e7u pour r\u00e9sister aux contraintes de la lyophilisation tout en garantissant \u00e0 la fois la stabilit\u00e9 du produit et l'int\u00e9grit\u00e9 du r\u00e9cipient tout au long du cycle.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Pour les produits biologiques et autres m\u00e9dicaments sensibles \u00e0 la temp\u00e9rature qui n\u00e9cessitent une distribution sous cha\u00eene du froid, la capacit\u00e9 du verre borosilicat\u00e9 de qualit\u00e9 moyenne \u00e0 conserver son int\u00e9grit\u00e9 structurelle sur une large plage de temp\u00e9ratures constitue un crit\u00e8re essentiel en mati\u00e8re de s\u00e9curit\u00e9 et de performance. <strong>PharGlass<\/strong> Les flacons en borosilicate de taille moyenne sont valid\u00e9s pour la lyophilisation, la conservation \u00e0 basse temp\u00e9rature et la st\u00e9rilisation finale.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">4.2 R\u00e9sistance hydrolytique sup\u00e9rieure et inertie chimique<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">La r\u00e9sistance \u00e0 l'hydrolyse d\u00e9signe la capacit\u00e9 du verre \u00e0 r\u00e9sister \u00e0 la d\u00e9gradation provoqu\u00e9e par l'eau et les solutions aqueuses \u2014 une propri\u00e9t\u00e9 essentielle pour tout r\u00e9cipient destin\u00e9 \u00e0 contenir des pr\u00e9parations m\u00e9dicamenteuses liquides pendant de longues p\u00e9riodes. Le verre borosilicat\u00e9 de type I est class\u00e9 comme pr\u00e9sentant la r\u00e9sistance \u00e0 l'hydrolyse la plus \u00e9lev\u00e9e parmi tous les types de verre pharmaceutique. Les limites fix\u00e9es pour les essais de r\u00e9sistance \u00e0 l'hydrolyse dans la Pharmacop\u00e9e europ\u00e9enne et la Pharmacop\u00e9e des \u00c9tats-Unis d\u00e9terminent la conformit\u00e9 du verre borosilicat\u00e9 de type I.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L'inertie chimique du verre borosilicat\u00e9 moyen pr\u00e9sente plusieurs avantages :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Faible teneur en substances extractibles et lixiviables (E&amp;L)<\/strong>: Contrairement aux plastiques, qui peuvent lib\u00e9rer des plastifiants, des antioxydants ou d\u2019autres additifs dans les formulations m\u00e9dicamenteuses, le verre pr\u00e9sente un profil d\u2019extractibles bien caract\u00e9ris\u00e9. Pour les produits biologiques sensibles tels que les anticorps monoclonaux et les vaccins, l\u2019interaction minimale avec le verre garantit que le profil chimique du produit reste inchang\u00e9 sur de longues p\u00e9riodes.<\/li>\n\n\n\n<li><strong>Compatibilit\u00e9 avec les formulations acides et neutres<\/strong>: Le verre borosilicat\u00e9 de type I convient \u00e0 la plupart des pr\u00e9parations parent\u00e9rales acides et neutres. Le r\u00e9cipient choisi pour une pr\u00e9paration donn\u00e9e doit \u00eatre tel que le verre ne lib\u00e8re pas de substances en quantit\u00e9s suffisantes pour alt\u00e9rer la stabilit\u00e9 de la pr\u00e9paration ou pr\u00e9senter un risque de toxicit\u00e9.<\/li>\n\n\n\n<li><strong>R\u00e9sistance aux attaques alcalines<\/strong>: While borosilicate glass is highly resistant to water and acids, its alkali resistance is also notable. Medium borosilicate glass meets Class A2 requirements for alkali resistance as defined by ISO 695, making it suitable for a wide range of drug formulations, including those with mildly alkaline pH.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The borosilicate glass\u2018s chemical resistance extends to resistance from water, acids, salt solutions, halogens, and organic solvents. Only hydrofluoric acid significantly attacks borosilicate glass, making it one of the most chemically inert packaging materials available to the pharmaceutical industry.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">4.3 Mechanical Robustness for High\u2011Speed Filling Lines<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In modern biopharmaceutical manufacturing, fill\u2011finish operations run at ever\u2011increasing speeds. High\u2011speed filling lines can achieve throughputs of up to 600 vials per minute for liquid or freeze\u2011dried products. At such rapid production rates, ensuring the mechanical integrity of every vial moving along the line is critical.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The tubular glass manufacturing process used for <strong>PharGlass<\/strong> vials produces containers with precise dimensional tolerances, smooth surfaces, and consistent wall thickness. These attributes contribute to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reduced line stoppages<\/strong>: Vials with inconsistent dimensions or rough surfaces are more likely to tip over, jam, or break during high\u2011speed filling. The dimensional precision of <strong>PharGlass<\/strong> tubular vials minimizes these risks.<\/li>\n\n\n\n<li><strong>Lower rejection rates<\/strong>: Cosmetic defects\u2014such as scratches, bubbles, or surface irregularities\u2014can trigger automated rejection in fill\u2011finish inspection systems. <strong>PharGlass<\/strong> employs 100% automated visual inspection to ensure that only vials meeting strict quality standards are shipped to customers.<\/li>\n\n\n\n<li><strong>Protection of high\u2011value drug products<\/strong>: In biopharma manufacturing, a single day of production delay due to filling line issues can cost approximately USD 800,000 in lost drug sales. Robust vials that perform reliably on filling lines directly protect this value.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Glass remains the optimal material for biopharma packaging, thanks to its hermeticity, transparency, strength, and chemical durability. For pharmaceutical manufacturers developing high\u2011value injectable products, the mechanical reliability of the glass container is as important as its chemical compatibility.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">4.4 Barrier Properties Against Moisture, Oxygen, and Light<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Pharmaceutical drug products can be degraded by exposure to three environmental factors: moisture, oxygen, and light. Medium borosilicate glass provides outstanding barrier protection against all three:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>barri\u00e8re anti-humidit\u00e9<\/strong>: Glass offers complete barrier protection against water vapor transmission, unlike plastic containers that have measurable water vapor transmission rates. For lyophilized (freeze\u2011dried) products, where even trace moisture can degrade the dried drug cake, the superior moisture barrier of glass is essential.<\/li>\n\n\n\n<li><strong>Oxygen barrier<\/strong>: Borosilicate glass is impermeable to oxygen, protecting oxygen\u2011sensitive APIs from oxidative degradation. As seen in comparative studies, products stored in glass retain potency significantly longer than those stored in plastics with measurable oxygen permeability.<\/li>\n\n\n\n<li><strong>Light protection<\/strong>: For photolabile drugs, <strong>PharGlass<\/strong> offers amber (color) medium borosilicate tubular glass vials that meet pharmacopoeial requirements for light transmission. Under the revised Ph. Eur. 3.2.1 spectral transmission test, colored glass containers are evaluated based on wall thickness rather than volume, ensuring consistent light protection across container sizes.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">4.5 Compatibility with Automated Pharmaceutical Processing<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In addition to filling line performance, the dimensional accuracy of tubular glass vials is critical for other automated processes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capping<\/strong>: Vials with consistent neck finish dimensions ensure proper seating of rubber stoppers and reliable crimping of aluminum seals, maintaining container\u2011closure integrity throughout the product\u2018s shelf life.<\/li>\n\n\n\n<li><strong>Lyophilization loading<\/strong>: Automated loading systems for freeze\u2011dryers require vials with precise outer dimensions to avoid jams and ensure uniform heat transfer during the lyophilization cycle.<\/li>\n\n\n\n<li><strong>Inspection systems<\/strong>: Automated visual inspection systems rely on consistent vial geometry to accurately detect foreign particles, cosmetic defects, and fill level deviations.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PharGlass<\/strong> medium borosilicate tubular glass vials are manufactured to strict dimensional tolerances, ensuring seamless integration with all major brands of pharmaceutical filling, capping, lyophilization, and inspection equipment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">5. Tubular vs. Molded Glass Vials: Understanding the Distinction<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pharmaceutical glass vials are manufactured by one of two processes: tubing (also known as tubular) or molding (also known as molded). Each process has distinct characteristics that may make it more or less suitable for specific applications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tubular glass vials\u2014such as those manufactured by <strong>PharGlass<\/strong>\u2014are produced by precision\u2011forming vials from continuous glass tubing. This process yields vials with exceptional dimensional consistency, smoother internal surfaces, and lighter weight compared to molded vials. Tubular vials are generally preferred for smaller volumes (2R through 30R), where dimensional precision is critical, and for applications where minimal vial weight reduces shipping costs and environmental impact.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Molded glass vials are formed by pressing molten glass into a mold, resulting in thicker walls and greater mechanical strength but less dimensional precision. Molded vials are typically used for larger volumes (50R and above) and for applications where extreme mechanical ruggedness is required.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For the vast majority of injectable drug products\u2014particularly biopharmaceuticals, vaccines, and high\u2011value specialty drugs\u2014medium borosilicate tubular glass vials offer the optimal balance of chemical performance, dimensional precision, and weight, making them the preferred choice of drug developers worldwide.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PharGlass<\/strong> specializes in tubular glass vials, offering a full range of sizes from 2R to 100R to meet the diverse needs of the pharmaceutical industry.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">6. Comparing Glass and Plastic Primary Packaging<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The choice between glass and plastic for primary pharmaceutical packaging is a subject of ongoing debate in the industry. However, for injectable drug products and other high\u2011risk pharmaceutical applications, glass\u2014particularly Type I borosilicate glass\u2014remains the undisputed standard.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Glass offers complete barrier protection against moisture and oxygen, is chemically inert under most conditions, and has a well\u2011characterized extractables\/leachables profile. Glass is suitable for high\u2011risk, injectable formulations, while plastic is generally preferred for solid or oral liquid dosage forms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Plastic containers, by contrast, may leach additives (plasticizers, antioxidants), absorb or adsorb active ingredients, or react with solvents and volatile excipients. Research has shown that plastic containers can compromise the efficacy of medicines by altering hydrogen\u2011bond network stability and electrical properties, reinforcing the preference for glass in long\u2011term storage applications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A comparative study of a multivitamin oral solution stored in PET bottles showed 7% degradation at three months under accelerated conditions, while the same product in amber Type I glass retained 98% potency\u2014demonstrating the superior protective performance of glass.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For pharmaceutical manufacturers developing injectable drug products\u2014including vaccines, monoclonal antibodies, and cell and gene therapies\u2014medium borosilicate tubular glass vials from <strong>PharGlass<\/strong> provide the highest level of product protection and regulatory acceptance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">7. Applications in the Pharmaceutical Industry<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">7.1 Biologics and Monoclonal Antibodies<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The biologic drugs market\u2014including monoclonal antibodies, fusion proteins, and recombinant therapeutics\u2014represents one of the fastest\u2011growing segments of the pharmaceutical industry. These high\u2011value, complex molecules are highly sensitive to environmental factors such as oxidation, light exposure, and container\u2011induced degradation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PharGlass<\/strong> medium borosilicate tubular glass vials provide the inert, low\u2011extractable, impermeable environment that biologics require for long\u2011term stability. The glass\u2018s low coefficient of thermal expansion allows for frozen storage and cold chain distribution without risk of container failure. Borosilicate glass is standard for biologics, offering low extractables and leachables profiles and compatibility with lyophilization cycles.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">7.2 Vaccines (mRNA, Viral Vector, and Traditional)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The global vaccine market\u2014accelerated by the COVID\u201119 pandemic and subsequent investments in mRNA and viral vector technologies\u2014has placed unprecedented demands on primary pharmaceutical packaging.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Medium borosilicate glass is the preferred material for vaccine packaging due to its ability to maintain sterility, withstand terminal sterilization processes, and provide complete barrier protection throughout the cold chain. Vials designed for ultra\u2011low temperature storage down to \u201380\u00b0C are specifically engineered to withstand the stresses of frozen storage, making them ideal for mRNA vaccines and viral vector vaccines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PharGlass<\/strong> supplies medium borosilicate tubular glass vials to vaccine manufacturers worldwide, with full regulatory documentation and validated performance for frozen storage and lyophilization.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">7.3 High\u2011Potency and Specialty Pharmaceuticals<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">For high\u2011potency active pharmaceutical ingredients (HPAPIs) and other specialty drug products, the integrity of the primary container is paramount. The chemical inertness and low extractables profile of medium borosilicate glass ensure that these sensitive molecules are not compromised by container\u2011induced degradation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The dimensional precision of <strong>PharGlass<\/strong> tubular vials also supports compatibility with containment isolators and robotic handling systems used for HPAPI filling, reducing operator exposure risk while maintaining product quality.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">7.4 Lyophilized (Freeze\u2011Dried) Products<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Lyophilization is a critical manufacturing process for many biologic drugs that are unstable in liquid formulations. The freeze\u2011drying process\u2014which involves freezing the liquid drug product, then removing water by sublimation under vacuum\u2014places significant mechanical stress on the glass container.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The tubular glass vial\u2018s design, including specially designed bottom radii and neck geometries, is engineered to add strength for freeze\u2011drying applications. <strong>PharGlass<\/strong> medium borosilicate vials are validated for lyophilization cycles, ensuring that the container maintains its integrity and barrier properties throughout the entire process.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">7.5 Advanced Therapies: Cell and Gene Therapies (CGT)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Cell and gene therapy products\u2014often manufactured in small batches, stored at cryogenic temperatures, and containing extremely high\u2011value active substances\u2014represent the frontier of pharmaceutical innovation. These products require primary packaging that can maintain integrity at temperatures as low as \u2013196\u00b0C (liquid nitrogen vapor phase) while preserving the viability and activity of living cells or genetic material.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PharGlass<\/strong> medium borosilicate tubular glass vials are validated for cryogenic compatibility, with glass formulations that resist thermal shock during freezing and thawing cycles. Low\u2011extractable borosilicate glass that conforms to USP Type I and ASTM Type I, Class A requirements is specifically designed for preserving biological materials.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">8. Quality Assurance and Regulatory Compliance at PharGlass<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">As a specialized manufacturer of pharmaceutical glass packaging, <strong>PharGlass<\/strong> operates under a comprehensive quality management system that meets the requirements of ISO 15378\u2014the international standard for primary packaging materials for medicinal products, incorporating GMP principles specific to pharmaceutical packaging.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Key quality control measures include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>100% Automated Visual Inspection<\/strong>: Every vial passes through high\u2011speed optical inspection systems that detect cracks, checks, bubbles, dimensional deviations, and cosmetic defects.<\/li>\n\n\n\n<li><strong>Batch\u2011Specific Testing<\/strong>: Each production batch is tested for hydrolytic resistance (in compliance with USP, Ph. Eur., and JP), internal pressure resistance, thermal shock resistance, and dimensional conformance.<\/li>\n\n\n\n<li><strong>Traceability<\/strong>: Full traceability from glass tubing lot to finished vial batch is maintained, enabling rapid response to quality issues and supporting customer regulatory submissions.<\/li>\n\n\n\n<li><strong>Change Control<\/strong>: All changes to manufacturing processes, materials, or suppliers are subject to rigorous change control procedures, with customer notification as required.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PharGlass<\/strong> provides comprehensive regulatory documentation for every shipment, including Certificates of Analysis, stability study reports (where applicable), and support for Type III Drug Master File (DMF) submissions to the US FDA. Packaging materials\u2014including glass\u2014must ensure that they do not contaminate or adversely affect the medicinal product. <strong>PharGlass<\/strong> is fully committed to meeting this regulatory expectation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">9. Sustainability in Pharmaceutical Glass Packaging<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Sustainability considerations are increasingly influencing packaging decisions in the pharmaceutical industry. Glass offers significant sustainability advantages:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>100% Recyclability<\/strong>: Glass is infinitely recyclable without loss of quality or performance. Recycled glass (cullet) reduces energy consumption in glass manufacturing and lowers the carbon footprint of glass packaging.<\/li>\n\n\n\n<li><strong>Inert and Non\u2011Leaching<\/strong>: Unlike some plastic packaging materials that may generate microplastics or leach additives, glass is chemically inert and does not contribute to environmental plastic pollution.<\/li>\n\n\n\n<li><strong>Lighter\u2011Weight Innovations<\/strong>: Manufacturers are developing thinner, lighter glass vials that maintain safety and performance standards while reducing material usage and shipping weight.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PharGlass<\/strong> is committed to sustainable manufacturing practices, including energy efficiency improvements, waste reduction, and increased use of recycled glass cullet in our production processes. The company also offers sustainably sourced packaging options for environmentally conscious customers.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sustainability efforts are increasingly becoming the foundation of strategy in the pharmaceutical packaging industry. The medium borosilicate medicinal glass tube industry is making strides by incorporating green practices into production processes, including emphasis on waste reduction, energy efficiency, and usage of recyclable products.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">10. Why Choose PharGlass for Medium Borosilicate Tubular Glass Vials?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>PharGlass<\/strong> is a trusted supplier of high\u2011quality medium borosilicate tubular glass vials to pharmaceutical and biotechnology companies worldwide. Our value proposition includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Superior Product Quality<\/strong>: All vials are manufactured from premium Type I borosilicate glass tubing and undergo 100% automated inspection to ensure consistent quality.<\/li>\n\n\n\n<li><strong>Comprehensive Regulatory Support<\/strong>: Full documentation for USP, Ph. Eur., and JP compliance, plus support for Type III DMF submissions to the US FDA.<\/li>\n\n\n\n<li><strong>Wide Product Range<\/strong>: Sizes from 2R to 100R in clear and amber glass, with customization options available for special applications.<\/li>\n\n\n\n<li><strong>Reliable Supply Chain<\/strong>: Robust manufacturing capacity and global logistics capabilities ensure on\u2011time delivery to customers worldwide.<\/li>\n\n\n\n<li><strong>Expertise technique<\/strong>: Experienced pharmaceutical packaging engineers available to assist with validation studies, compatibility testing, and regulatory submissions.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">When you choose <strong>PharGlass<\/strong> medium borosilicate tubular glass vials for your injectable drug product, you are selecting a primary packaging partner dedicated to patient safety, product stability, and manufacturing excellence.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Conclusion<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Medium borosilicate tubular glass vials play an essential role in the pharmaceutical industry as the primary container of choice for injectable drugs, biologics, vaccines, and advanced therapies. Their exceptional thermal stability, chemical inertness, mechanical robustness, and barrier properties make them uniquely suited to the demanding requirements of modern pharmaceutical manufacturing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As the pharmaceutical industry continues to develop increasingly complex and sensitive drug products\u2014from monoclonal antibodies and mRNA vaccines to cell and gene therapies\u2014the need for high\u2011quality primary packaging will only intensify. <strong>PharGlass<\/strong> is committed to meeting this need with superior medium borosilicate tubular glass vials, backed by rigorous quality systems, comprehensive regulatory expertise, and a dedication to customer success.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>For technical specifications, sample requests, or to discuss your pharmaceutical packaging requirements with our team of glass packaging experts, please contact <strong>PharGlass<\/strong> today.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Le r\u00f4le essentiel du conditionnement primaire des produits pharmaceutiques Dans l'industrie pharmaceutique, le r\u00e9cipient qui contient un m\u00e9dicament est bien plus qu'un simple contenant passif. \u2026 <a title=\"Flacons tubulaires en verre borosilicat\u00e9 de taille moyenne : un \u00e9l\u00e9ment essentiel pour la stabilit\u00e9 des m\u00e9dicaments injectables et la s\u00e9curit\u00e9 des patients\" class=\"read-more\" href=\"https:\/\/www.pharglass.com\/fr\/medium-borosilicate-tubular-glass-vials-an-essential-enabler-of-injectable-drug-stability-and-patient-safety\/\" aria-label=\"En savoir plus sur Medium Borosilicate Tubular Glass Vials: An Essential Enabler of Injectable Drug Stability and Patient Safety\">Lire plus<\/a><\/p>","protected":false},"author":1,"featured_media":2292,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["post-2291","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry-standards","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50"],"_links":{"self":[{"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/posts\/2291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/comments?post=2291"}],"version-history":[{"count":1,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/posts\/2291\/revisions"}],"predecessor-version":[{"id":2293,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/posts\/2291\/revisions\/2293"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/media\/2292"}],"wp:attachment":[{"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/media?parent=2291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/categories?post=2291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pharglass.com\/fr\/wp-json\/wp\/v2\/tags?post=2291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}